Evidence map›Paper›PMID 41982541›Full record

ArticleFrontiers in medicine2026

Influence of chemotherapy intensity on opportunistic fungal infection risk in non-small cell lung carcinoma: a retrospective study.

Fang Zheng, Wenli Li, Fei Zhao, Zhenzhen Zhu, Weiyang Wang, Qinghai You

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fang ZhengDepartment of Respiratory and Critical Care Medicine, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Wenli LiDepartment of Thoracic Oncology, The Fifth Affiliated Hospital of Anhui Medical University, Fuyang, China.
Fei ZhaoDepartment of Respiratory and Critical Care Medicine, Anhui Provincial Chest Hospital, Hefei, China.
Zhenzhen ZhuDepartment of Respiratory and Critical Care Medicine, Anhui Provincial Chest Hospital, Hefei, China.
Weiyang WangDepartment of Respiratory and Critical Care Medicine, Anhui Provincial Chest Hospital, Hefei, China.
Qinghai YouDepartment of Respiratory and Critical Care Medicine, First Affiliated Hospital of Anhui Medical University, Hefei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Opportunistic fungal infections represent a serious treatment-related complication in patients with advanced non-small cell lung carcinoma (NSCLC) undergoing chemotherapy, closely associated with treatment intensity-induced immunosuppression. Objectives: To investigate the influence of relative dose intensity (RDI) of first-line platinum-based doublet chemotherapy on the risk of invasive fungal infection (IFI) in patients with stage IIIB-IV NSCLC and its underlying mechanisms. Methods: A total of 195 patients with stage IIIB-IV NSCLC who received first-line platinum-based doublet chemotherapy between January 2022 and December 2025 were enrolled. Based on the average RDI of chemotherapy, patients were categorized into high-intensity (RDI > 85%, Results: The incidence of IFI was higher in the high-intensity group than in the low-intensity group (χ Conclusion: In patients with advanced NSCLC, high relative dose intensity of first-line chemotherapy is independently associated with an increased risk of invasive fungal infection. This association is partly mediated by treatment-induced myelosuppression and is accompanied by a significant increase in clinical burden.

Indexed as

chemotherapy intensityinvasive fungal infectionmyelosuppressionnon-small cell lung carcinomarelative dose intensityretrospective study

Identifiers

PMID41982541
PMCPMC13070931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.